ZNF219

Across TCGA pan-cancer cohorts, ZNF219 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF219 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ZNF219 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF219 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, STAD, and LUSC are the cancer types where ZNF219 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
STAD	OS	Median	All	0.003	0.667	<.001	24	view →
LUSC	DFS	Median	All	0.124	0.748	<.001	24	view →
LUAD	DFS	Median	II,III,IV	0.129	0.684	<.001	21	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
UCEC	DFS	Median	All	1.000	0.831	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZNF219–THYM (OS)

Open the THYM breakdown →